Acorda Therapeutics, Inc.
ACOR
Pozycja w akcjach
#39162
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Cena akcji
$0.879
Ostatnia synchronizacja: 2024-05-07
Kapitalizacja rynkowa
$582.38K
Zmiana (1 dzień)
9.88%
Zmiana (1 rok)
8,690.00%
Kraj
US
Handel Acorda Therapeutics, Inc. (ACOR)
Kategoria
Healthcare
Zyski dla Acorda Therapeutics, Inc. (ACOR)
Zyski w Mar 2024 TTM: $-304.44M
Według najnowszych raportów finansowych Acorda Therapeutics, Inc., obecny zysk firmy wynosi $-304.44M. W roku 2022 firma osiągnęła zysk w wysokości $-35.25M, wzrost w porównaniu do zysku z roku 2021, który wynosił $-109.07M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Acorda Therapeutics, Inc. od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-304.44M | 2.84% |
| 2023 | $-296.02M | 739.85% |
| 2022 | $-35.25M | -67.69% |
| 2021 | $-109.07M | 1.31% |
| 2020 | $-107.67M | -60.74% |
| 2019 | $-274.25M | -1,442.84% |
| 2018 | $20.42M | -108.11% |
| 2017 | $-251.89M | 495.92% |
| 2016 | $-42.27M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -679.61% |
IN
|
